JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis

Blood

Volumn 124, Issue 19, 2014, Pages 2987-2995

  Wang, Xiaoli ^a   Ye, Fei ^a   Tripodi, Joseph ^a   Hu, Cing Siang ^a   Qiu, Jiajing ^a   Najfeld, Vesna ^a   Novak, Jesse ^a   Li, Yan ^a   Rampal, Raajit ^b   Hoffman, Ronald ^a  

^a Tisch Cancer Institute   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CD34 ANTIGEN; JANUS KINASE 2 INHIBITOR; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; DRUG EFFECT; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; MALE; MOUSE; MYELOFIBROSIS; NONHUMAN; SPLEEN; STEM CELL; ADULT; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SIGNAL TRANSDUCTION; THROMBOCYTOSIS;

ADULT; AGED; APOPTOSIS; CELLS, CULTURED; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SPLEEN; STEM CELLS; THROMBOCYTOSIS;

EID: 84909584695     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-558015     Document Type: Article

References (40)

1. Anastasi J, Hoffman R. Progress in the classification of myeloid neoplasms: clinical implications. In: Hoffman R, Benz E Jr, Silberstein L, Heslop H, Weitz J, Anastasi J, eds. Hematology: Basic Principles and Practice, 6th ed New York, NY: Saunders, An Imprint of Elsevier; 2012:722-727.
2. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005;19(19):1-13.
3. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002;76(suppl 2):193-203.
4. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(100):4272-4290.
5. Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol. 1999;6(2):100-109.
6. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255-1265.
7. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
8. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-1538.
9. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584-596.
10. Marty C, Lacout C, Martin A, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116(5):783-787.
11. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281.
12. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660.
13. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 2006;1:e18.
14. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111(111):5109-5117.
15. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
16. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
17. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468.
18. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(108):3472-3476.
19. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med. 2010;363(12):1189-1190.
20. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(116):988-992.
21. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
22. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
23. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(366):787-798.
24. Verstovsek S, Mesa RA, Gotlib J, et al. A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
25. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(13):311-320.
26. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(29):789-796.
27. Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012;122(122):3888-3899.
28. Barosi G, Rosti V, Massa M, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;124(124):618-625.
29. Thiele J, Pierre R, Imbert M, et al. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris N, Stan N, Vardiman JW, eds. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Washington, DC: IARC Press; 2001;35-38.
30. Wang X, Zhang W, Tripodi J, et al. Sequential treatment of CD341 cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010;116(26):5972-5982.
31. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32-38.
32. Wang X, LeBlanc A, Gruenstein S, et al. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol. 2009;37(10):1194-1200.
33. Najfeld V, Coyle T, Berk PD. Transformation of polycythemia vera to acute nonlymphocytic leukemia accompanied by t (1;3) (p36;q21) karyotype. Cancer Genet Cytogenet. 1988;33(2):193-200.
34. Li Z, Xu M, Xing S, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007;282(6):3428-3432.
35. Kantarjian H, Sawyers C, Hochhaus A, et al; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-652.
36. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565-5572.
37. Manshouri T, Quintás-Cardama A, Nussenzveig RH, et al. The JAK kinase inhibitor CP-690, 550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008;99(6):1265-1273.
38. Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014;124(124):771-779.
39. Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(122):4047-4053.
40. Anand S, Stedham F, Gudgin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood. 2011;118(118):1610-1621.